SAN MATEO, Calif. – The U.S. Food and Drug Administration has cleared Adherium’s Smartinhale sensor for over-the-counter sales. The sensor was cleared for use in AstraZeneca’s Symbicort aerosol inhaler to monitor and promote asthma and COPD medication adherence as part of a self-management plan. It automatically records the date and time the inhaler is used and sends the information to an app on the user’s smartphone or tablet. “Over-the-counter sales of our Smartinhaler sensor for the Symbicort aerosol inhaler continues the advancement of our vision for stronger partnerships between patients and physicians by making adherence to personal management plans easier,” said Arik Anderson, CEO of Adherium, in a statement. “We are now well positioned to launch in the U.S., following successes in Europe and Australia.” OTC clearance means that Adherium’s Smartinhaler can now be sold directly to consumers, including through pharmacies and online, without the need for the patient to first obtain a prescription.
WILMINGTON, Del. – With the recent launch of a new asthma app for patients, Nemours Children’s Health System has set in motion a plan to integrate all of its digital offerings into one patient-facing platform over the next year.
“Until now, Nemours’ digital assets existed in their own space,” said Gina Altieri, senior vice president and chief of strategy integration at Nemours Children’s Health System, which serves Delaware, New Jersey, Pennsylvania and Flordia. “We realized that by integrating them, we could create a seamless, user-friendly experience.”
The health provider’s digital assets include: a Nemours CareConnect telehealth app; a KidsHealth.org website; and an industry-recognized electronic health record.
The Nemours App for Asthma captures data from home monitoring devices like digitally-connected stethoscopes in real-time and shares the information with providers. Patients and their caregivers can use the app to: review video or written instructions for the proper use of home health devices; keep a real-time journal of asthma triggers and symptoms to share with physicians; conduct live telehealth video visits; and review the child’s EHR.
Nemours plans to monitor the care of families using the app to determine how the tool helps patients manage and control their condition compared with traditional care, with an eye toward treating other conditions.
“Right now our focus is on the Nemours App for Asthma, but the vision for diabetes and cardiac-focused apps is similar: use the technology to help families more easily and effectively control their child’s disease,” Altieri said.
Nemours digital health strategy is focused on putting more digital tools into the hands of families who expect it. In addition to the planned chronic condition apps, the provider will also develop a primary care app next year.
“Consumerism is changing everything, including health care,” Altieri said.
ORLANDO, Fla. – Nemours Children’s Health System has launched a mobile app to help clinicians and families of children with asthma monitor their health remotely, adhere to care plans and communicate more effectively between visits. The Nemours App for Asthma, currently being piloted, is part of the health system’s digital health strategy. “This app is a model for Nemours, demonstrating how digital health allows us to meet families wherever they are and fulfill our commitment to the medical home model,” said Gina Altieri, senior vice president and chief of strategy integration at Nemours Children’s Health System, in a statement. “Our goal is to better engage with families, understand what is happening between visits, help families manage chronic conditions and improve outcomes of care.” The asthma app supports the use of physician ordered home-monitoring tools, such as a breath-flow monitor and a digitally connected stethoscope, provides video instructions for inhaler use, allows families to keep a real-time digital journal of symptoms and enables better communication for telehealth visits with asthma specialists. The app is the first of several disease-specific tools designed to help patients and families better manage their chronic conditions by integrating the patient and clinician experience into one platform. The app will be released in early 2018.
MADISON, Wis. –Propeller Health has extended its collaboration with respiratory medicine provider GSK.
The two companies began working together in 2015 to research and collect evidence from Propeller’s clip-on sensor and software platform used in conjunction with GSK’s ELLIPTA inhaler and respiratory medicines for asthma and COPD.
“We are excited to be working closely with GSK to make the sensor for the ELLIPTA inhaler available in our commercial programs, and for the first time, as part of commercial pilots with GSK outside the U.S.,” said David Van Sickle, CEO and co-founder of Propeller, in a statement.
The clip-on sensor for the ELLIPTA Inhaler automatically records medication use, which the Propeller platform analyzes and presents to patients and physicians through its data-driven digital interfaces, providing an in-depth view into adherence.
The Propeller sensor and software program for the ELLIPTA Inhaler received CE marking and clearance from the U.S. Food and Drug Administration last year.
“Digital innovations, like sensor technologies, will help us ensure patients receive the best possible package of care management and treatment for their respiratory condition,” said Eric Dube, senior vice president and head of GSK, in a statement.
NEW BRUNSWICK, N.J. – Scientists at Rutgers University have developed a grapheme-based sensor that could predict an asthma attack.
The miniaturized electrochemical sensor accurately measures exhaled breath condensate using reduced grapheme oxide, which resists corrosion, has superior electrical properties and accurately detects biomarkers.
“Nitrite level in breath condensate is a promising biomarker for inflammation in the respiratory tract,” said Clifford Weisel, professor at Rutgers’ Environmental and Occupational Health Sciences Institute and co-author of a recently published study describing the invention.
“Having a rapid, easy method to measure it can help an asthmatic determine if air pollutants are affecting them so they can better manage use of medication and physical activity.”
The next step for the researchers is to develop a portable, wearable system, which could be commercially available in five years, said Mehdi Javanmard, a researcher on the team, in a statement.
“Our vision is to develop a device that someone with asthma or another respiratory disease can wear around their neck or on their wrist and blow into it periodically to predict the onset of an asthma attack or other problems,” he said. “It advances the field of personalized and precision medicine.”
MINNEAPOLIS – Connected health solutions provider HealthFactors and Koronis Biomedical Technologies have announced a collaboration to improve health care and outcomes for people with respiratory conditions associated with asthma, COPD and cystic fibrosis. The companies will work on developing products and initiatives including algorithms that are used in smart inhalers. “Breakthrough treatments for complex medical conditions are being driven by a marriage of leading-edge electronic and software technology and advanced algorithms that deliver information from devices to patients, health providers, families and caregivers,” said Patrick Lichter, co-founder, president and chief technology officer of KBT, in a statement. “This type of digital solution surrounds the patient and creates a truly connected experience that factors in all aspects of their lives and health care journey.” Throughout the collaboration, HealthFactors and KBT will partner with device manufacturers, pharmaceutical companies, researchers and clinicians who are focused on emerging treatments and therapies for respiratory and other complex medical conditions.
MINNEAPOLIS, Minn. – HealthFactors and Koronis Biomedical Technologies will work together on a variety of products and initiatives to improve health care and outcomes for people living with respiratory conditions associated with asthma, COPD and cystic fibrosis. “Our collaboration with KBT blends decades of expertise in technology, engineering, research, health care delivery and pharmaceuticals to deliver patient-centered solutions,” said Dan Spors, chief commercial officer of HealthFactors, in a statement. The collaboration will include the development of algorithms that are used in smart inhalers, and several clinical and technology advancements needed for the implementation of these inhalers into mainstream clinical practice. “Breakthrough treatments for complex medical conditions are being driven by a marriage of leading-edge electronic and software technology and advanced algorithms that deliver information from devices to patients, health care providers, families and caregivers,” said Patrick Lichter, president, co-founder and chief technology officer at KBT, in a statement.
NEW YORK – Researchers at the Icahn School of Medicine at Mount Sinai have successfully conducted a study of asthma patients using the Apple ResearchKit framework and its Asthma Health app.
The results of the study showed that a smartphone-only approach was successful for large-scale participant enrollment across the country, secure bi-directional data exchange between study investigators and app users, and the collection of other information such as geolocation, air quality and device data, said Eric Schadt Ph.D., senior author of a paper about the study published recently in Nature Biotechnology.
“The Asthma Mobile Health study represents the coming together of academia and industry to benefit from the ubiquity of smartphones and harness the power of citizen-science to modernize the clinical research process,” said Eric Schadt, Ph.D., senior author of a paper about the study published recently in Nature Biotechnology, in a statement.
Launched in March 2015, the Asthma Mobile Health study included regular surveys to understand how asthma patients were affected by and treating their condition over time. Nearly 50,000 iPhone users downloaded the app in the first six months of the study.
More than 7,500 patients enrolled in the study, and 85% of them completed at least one survey. A core group of 2,317 users filled out multiple surveys during the course of the study.
“Our study demonstrates the power of mobile health tools to scale and accelerate clinical research so that we can derive the evidence needed to inform clinical practice and improve patient care,” said Dr. Yvonne Chan, Ph.D., director of digital health and personalized medicine at the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai and principal investigator for the study, in a statement.
‘Our long-term strategy is to become a global leader in digital health solutions’
MELBOURNE, Australia – As a lifelong asthma patient, Adherium CEO Garth Sutherland was excited to see his company’s Smartinhaler chosen for the myAirCoach program, part of the European Union’s Horizon 2020 Framework for Research and Innovation. He spoke with us recently about the role of technology in asthma and COPD management, and what’s next for his company.
HHTN: What does being chosen to participate in the myAirCoach program mean for Adherium and the Smartinhaler?
Sutherland: For such an eminent group of European Key Opinion Leaders to choose Smartinhaler to assess the impact of digital health solutions on asthma control and exacerbations is a major validation, not only of the role digital technologies can play in managing chronic respiratory diseases like asthma, but also in Smartinhaler as the leading solution in this space.
HHTN: How is the Smartinhaler unique to the market?
Sutherland: Current medical data technologies still have not fulfilled their potential for improving patient engagement. Several smart devices are available, but patient engagement remains elusive. With more than 15 years of experience and product in use in more than 30 countries, Adherium can leverage its extensive respiratory data set across the medical information value chain, aiming to deliver invaluable insights to patients to engage and trigger positive behaviour changes. Smartinhaler is also drug/brand agnostic and has matching devices for a range of inhaled drugs and inhaler types
HHTN: How is technology impacting home health care?
Sutherland: A perfect example of this is the myAirCoach program, which is to be a personalized user-friendly, cost-efficient and lightweight health self-management system that can give confidence to patients on how to manage their asthma to improve their day-to-day quality of life. The aim is to revolutionise asthma treatment by focusing on patient empowerment and engagement by introducing asthma monitoring and control in daily life to assess real-time fluctuations in asthma symptoms coupled with medication use, and to empower patients to promptly intervene through self-management advice to prevent exacerbations, asthma attacks or hospitalizations. The program also illustrates how technology is personalizing treatment and interaction with doctors, as myAirCoach will integrate Adherium’s Smartinhaler sensing infrastructure into clinical prediction models to provide personalized feedback to patients on how to manage their disease, perhaps guided by a virtual healthcare professional, decreasing the need to have frequent face-to-face contact with healthcare professionals.
HHTN: How is technology impacting health care for people with asthma?
Sutherland: Digital monitoring and interventions will become the chronic disease management standard of care in the not-too-distant future. Adherium improves the lives of people with asthma and COPD through real-time delivery of invaluable insights that will increase their awareness of their clinical state, as well as the adherence and effectiveness of medical treatment they follow.
HHTN: What’s next for Adherium?
Sutherland: Research and development is continuing on our next generation miniaturized devices for new inhalers and embedded devices, with enhanced features and sensor functionality to increase data collection. This includes our latest device, which is set to be launched this year, which has sensors for orientation sensing (or use) and inhalation detection for true dose confirmation, but this will only provide modest additional information beyond the objective record of drug use currently recorded. Our long-term strategy is to become a global leader in digital health solutions.
MELBOURNE, Australia – Adherium’s Smartinhaler is playing an integral role in a major European Union program to determine if mHealth systems can be used to help manage asthma.
“For such an eminent group of European Key Opinion Leaders to choose Smartinhaler to assess the impact of digital health solutions on asthma control and exacerbations is a major validation, not only of the role digital technologies can play in managing chronic respiratory diseases like asthma, but also in Smartinhaler as the leading solution in this space,” said Garth Sutherland, founder and CEO of Adherium.
The Smartinhaler is being used for the myAirCoach program, part of the EU’s Horizon 2020 Framework for Research and Innovation. The program is funded through the Horizon 2020 framework, which is the largest EU Research and Innovation program ever established.
Adherium’s Smartinhaler technology offers sensors for metered dose inhalers, dry powder inhalers and nebulizers, and works with a wireless platform for real-time data collection and reporting.
The company will supply a range of products to the myAirCoach program, including devices for inhaled medications manufactured by AstraZeneca and GSK.
The myAirCoach program, is coordinated by the Centre for Research and Technology Hellas (CERTH) in Thessaloniki, Greece, and supported by a group of asthma patients acting as advisors. It will explore whether home monitoring and mHealth systems can be used to predict asthma control and the occurrence of asthma exacerbations. The impact of the program is expected to become the basis for the widespread adoption of sensor-based self-management systems across the spectrum of respiratory diseases.
“Digital monitoring and interventions will become the chronic disease management standard of care,” said Sutherland. He said that his company already improves the lives of people with asthma and COPD through real-time delivery of invaluable insights that help with adherence and effectiveness of medical treatment they follow.